CZECRIN/PharmAround workshop

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

DEMLOVÁ Regina DEML Jiří OBERMANNOVÁ Radka

Year of publication 2022
Type Workshop
MU Faculty or unit

Faculty of Medicine

Citation
Description As part of the 46th annual Brno Oncology Days (BOD) 12-14 On October 10, 2022, CZECRIN/PharmAround organized a workshop on the topic: "The year 2022 brings fundamental changes in the conduct of clinical trials (not only) in the Czech Republic". MUDr led the first lecture. Beata Čečetková, Ph.D., presented the results of a current study by the Association of Innovative Pharmaceutical Industry (AIFP) focused on an overview of clinical drug evaluations in the Czech Republic. The study showed that in 2021, AIFP member companies implemented 396 clinical evaluations, mainly in oncology, infectious diseases, and nervous system diseases. Representatives of the Dubanská&co law firm presented the second input focused on new legislation in clinical studies. This should make the entire process of approval and implementation of clinical trials more efficient and transparent. MUDr presented the third block of the workshop. Radka Obermannová, Ph.D., head physician of Phase I Studies ("First in human") at the Masaryk Institute of Oncology. In her lecture, she mentioned the 10th anniversary of this unit and compared the Phase I Study ten years ago and today. The design of Phase I studies allows for intraindividual escalation and thus begins to approach clinical practice, which fulfills its goal. "Challenges for clinical studies or it will not work without cooperation" was the topic of the last doc lecture. MD Regina Demlová, Ph.D. She reminded us that International Clinical Trials Day is celebrated every year on May 20 in honor of the start of the Scottish physician James Lind's first controlled trial in 1747. "Currently, clinical studies in the Czech Republic are at a high-level thanks to high-quality source data, very good relations between doctors and patients, and especially thanks to the intensive cooperation between all participants in clinical studies, which is necessary for the successful implementation of the study," summarizes Associate Professor Demlová.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.